Validation of the IHE cohort model of type 2 diabetes and the impact of choice of macrovascular risk equations

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Lundqvist, Adam ^a   Carlsson, Katarina Steen ^a,b   Johansen, Pierre ^a   Andersson, Emelie ^a   Willis, Michael ^a  

^a SWEDISH INSTITUTE FOR HEALTH ECONOMICS   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; DIABETIC ANGIOPATHY; EXTERNAL VALIDITY; HUMAN; MACROVASCULAR RISK EQUATION; MATHEMATICAL PARAMETERS; MICROANGIOPATHY; MICROSIMULATION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROGNOSIS; SIMULATION; VALIDATION PROCESS; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES COMPLICATIONS; INCIDENCE; REPRODUCIBILITY; RISK; THEORETICAL MODEL;

CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; HUMANS; INCIDENCE; MODELS, THEORETICAL; PATIENT OUTCOME ASSESSMENT; REPRODUCIBILITY OF RESULTS; RISK;

EID: 84908007386     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110235     Document Type: Article

References (35)

1. Drummond MF, Sculpher MJ, Torrance G.W., O'Brien BJ, Stoddart GL, et al. (2005) Methods for the economic evaluation of health care programme. Third edition: Oxford: Oxford University Press.
2. American Diabetes Association Consensus Panel (2004) Guidelines for Computer Modeling of Diabetes and its Complications. Diabetes care 27: 2262-2265.
3. Stahl JE (2008) Modelling methods for pharmacoeconomics and health technology assessment: an overview and guide. Pharmacoeconomics 26: 131-148.
4. Siebert U, Alagoz O, Bayoumi A.M., Jahn B., Owens DK, et al. (2012) Statetransition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. Value Health 15: 812-820.
5. Eddy DM, Hollingworth W, Caro J.J., Tsevat J., McDonald KM, et al. (2012) Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Value Health 15: 843-850.
6. Clarke PM, Gray AM, Briggs A, Farmer A.J., Fenn P., et al. (2004) A model to Estimate the Lifetime Health Outcomes of Patients with Type 2 Diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 47: 1747-1759.
7. Hayes AJ, Leal J, Gray A.M., Holman RR, Clarke P.M. (2013) UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia 56: 1925-1933.
8. Ahmad Kiadaliri A., Gerdtham UG, Nilsson P, Eliasson B., Gudbjornsdottir S, et al. (2013) Towards renewed health economic simulation of type 2 diabetes: risk equations for first and second cardiovascular events from Swedish register data. PLoS One 8: e62650.
9. Eastman RC, Javitt JC, Herman W.H., Dasbach EJ, Zbrozek AS, et al. (1997) Model of Complications of NIDDM. I. Model Construction and Assumptions. Diabetes Care 20: 725-734.
10. Bagust A, Hopkinson PK, Maier W, Currie C.J. (2001) An Economic Model of the Long-Term Health Care Burden of Type II Diabetes. Diabetologia 44: 2140-2155.
11. Tarride JE, Hopkins R, Blackhouse G., Bowen JM, Bischof M, et al. (2010) A review of methods used in long-term cost-effectiveness models of diabetes mellitus treatment. Pharmacoeconomics 28: 255-277.
12. Palmer AJ, Mount Hood 5 Modeling G, Clarke P, Gray A, Leal J, et al. (2013) Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting. Value Health 16: 670-685.
13. Caro JJ, Briggs AH, Siebert U, Kuntz K.M. (2012) Modeling Good Research Practices-Overview: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research 15: 796-803.
14. Eddy DM, Schlessinger L. (2003) Validation of the archimedes diabetes model. Diabet Car 26: 3102-3110.
15. Palmer AJ, Roze S, Valentine W.J., Minshall ME, Foos V, et al. (2004) Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 20 Suppl 1: S27-40.
16. Hoerger TJ, Segel JE, Zhang P, Sorensen S.W. (2009) Validation of the CDC-RTI Diabetes Cost-Effectiveness Model. RTI Press publication No. MR-0013-0909. Research Triangle Park, NC: RTI International.
17. Grant D, Foos V, Palmer J., Lloyd A, Evans M, et al. (2012) Long-term validation of the IMS CORE Diabetes Model in Type 1 and Type 2 diabetes. Presented at the 72nd Scientific Sessions of the American Diabetes Association (ADA), Philadelphia, PA, USA, June 8-12.
18. Willis M, Asseburg C, He J (2013) Validation of economic and health outcomes simulation model of type 2 diabetes mellitus (ECHO-T2DM). J Med Econ 16: 1007-1021.
19. Mount Hood 4 Modeling Group (2007) Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabetes Care 30: 1638-1646.
20. Klein R, Klein BE, Moss S.E., Davis MD, DeMets D.L. (1984) The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 91: 1464-1474.
21. Palumbo PJ, Elveback LR, Chu C.P., Connolly DC, Kurland L.T. (1976) Diabetes mellitus: incidence, prevalence, survivorship, and causes of death in Rochester, Minnesota, 1945-1970. Diabetes 25: 566-573.
22. Eeg-Olofsson K.C., Cederholm J, Nilsson P.M., Zethelius B., Svensson A-M, et al. (2010) New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). Journal of Internal Medicine 268: 471-482.
23. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-853.
24. Holman RR, Paul SK, Bethel M.A., Matthews DR, Neil H.A. (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359: 1577-1589.
25. Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse J.B., et al. (2011) Longterm effects of intensive glucose lowering on cardiovascular outcomes. The New England journal of medicine 364: 818-828.
26. Advance Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, et al. (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358: 2560-2572.
27. Knopp RH, d'Emden M, Smilde JG, Pocock S.J. (2006) Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes care 29: 1478-1485.
28. Colhoun HM, Betteridge DJ, Durrington P.N., Hitman GA, Neil HA, et al. (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364: 685-696.
29. Kahn SE, Haffner SM, Heise M.A., Herman WH, Holman RR, et al. (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. The New England journal of medicine 355: 2427-2443.
30. Sasaki AU, Uehara M, Horiuchi N., Hasegawa K, Shimizu T. (1997) A 15-year follow-up study of patients with non-insulin-dependent diabetes mellitus (NIDDM) in Osaka, Japan. Diabetes research and clinical practice 36: 41-47.
31. Davis WA, Knuiman MW, Davis T.M. (2010) An Australian cardiovascular risk for type 2 diabetes: the Fremantle Diabetes Study. Intern Med J 40: 286-292.
32. Kengne AP, Patel A, Colagiuri S., Heller S, Hamet P, et al. (2010) The Framingham and UK Prospective Diabetes Study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) Study. Diabetologia 53: 821-831.
33. Simmons RK, Coleman RL, Price H.C., Holman RR, Khaw KT, et al. (2009) Performance of the UK Prospective Diabetes Study Risk Engine and the Framingham Risk Equations in Estimating Cardiovascular Disease in the EPIC-Norfolk Cohort. Diabetes Care 32: 708-713.
34. van der Heijden AA, Ortegon MM, Niessen L.W., Nijpels G., Dekker J.M. (2009) Prediction of coronary heart disease risk in a general, pre-diabetic, and diabetic population during 10 years of follow-up: accuracy of the Framingham, SCORE, and UKPDS risk functions: The Hoorn Study. Diabetes Care 32: 2094-2098.
35. van Dieren S., Peelen LM, Nothlings U, van der Schouw YT, Rutten GE, et al. (2011) External validation of the UK Prospective Diabetes Study (UKPDS) risk engine in patients with type 2 diabetes. Diabetologia 54: 264-270.